Latest Ratios: P/E Ratio 6.5x · EV/EBITDA N/A · ROE 17.1%. (1998–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $68M | $80M | $54M | $84M | $58M | $58M | $59M | $108M | $87M | $79M | $62M |
| Enterprise Value | $96M | $108M | $65M | $87M | $106M | $74M | $132M | $198M | $107M | $38M | $16M |
| P/E Ratio → | 6.55 | 6.27 | — | 5.12 | — | — | — | — | — | — | — |
| P/S Ratio | 4.15 | 4.92 | 3.02 | 9.70 | 12.75 | 0.95 | 1.00 | 2.12 | 14.73 | 16.02 | — |
| P/B Ratio | 1.04 | 1.00 | 0.77 | 1.32 | 1.36 | 1.04 | 0.92 | 1.67 | 1.35 | 1.19 | 1.68 |
| P/FCF | — | — | — | — | 2.02 | — | 13.47 | — | — | — | — |
| P/OCF | — | — | — | — | 1.97 | — | 4.47 | 40.28 | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 6.65 | 3.62 | 10.08 | 23.49 | 1.22 | 2.24 | 3.88 | 18.02 | 7.77 | — |
| EV / EBITDA | — | — | — | — | — | 15.08 | 15.38 | 40.25 | — | — | — |
| EV / EBIT | — | 5.48 | 18.49 | 4.21 | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | 3.73 | — | 30.11 | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | -0.7% | -0.7% | 5.5% | -17.7% | -46.5% | 55.1% | 11.5% | 17.4% | -44.6% | 3.0% | — |
| Operating Margin | -49.0% | -49.0% | -43.9% | -129.4% | -193.6% | -6.1% | -3.7% | -8.4% | -176.4% | -93.5% | — |
| Net Profit Margin | 79.0% | 79.0% | -7.8% | 320.1% | -329.8% | -12.0% | -22.0% | -13.4% | -186.5% | -308.6% | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 17.1% | 17.1% | -2.1% | 52.3% | -30.5% | -12.1% | -20.0% | -10.6% | -16.9% | -29.5% | 31.2% |
| ROA | 8.8% | 8.8% | -1.0% | 18.2% | -9.0% | -4.1% | -6.9% | -4.3% | -10.5% | -19.2% | 11.0% |
| ROIC | -6.3% | -6.3% | -7.9% | -10.7% | -8.1% | -2.7% | -1.1% | -2.7% | -14.3% | -42.4% | — |
| ROCE | -5.8% | -5.8% | -6.0% | -8.1% | -6.3% | -2.5% | -1.3% | -3.0% | -10.7% | -8.5% | -17.1% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.78 | 0.78 | 0.87 | 0.99 | 1.68 | 0.74 | 1.76 | 1.57 | 0.97 | 0.08 | 0.94 |
| Debt / EBITDA | — | — | — | — | — | 8.29 | 13.21 | 20.72 | — | — | — |
| Net Debt / Equity | — | 0.35 | 0.15 | 0.05 | 1.15 | 0.30 | 1.13 | 1.38 | 0.30 | -0.61 | -1.25 |
| Net Debt / EBITDA | — | — | — | — | — | 3.35 | 8.50 | 18.27 | — | — | — |
| Debt / FCF | — | — | — | — | 1.71 | — | 16.64 | — | — | — | — |
| Interest Coverage | 4.76 | 4.76 | 0.81 | 3.42 | -1.58 | -1.62 | -1.91 | -0.45 | -9.90 | -1.95 | -1.94 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 14.34 | 14.34 | 15.26 | 16.69 | 4.29 | 2.68 | 2.40 | 2.35 | 7.47 | 11.87 | 1.80 |
| Quick Ratio | 14.34 | 14.34 | 14.57 | 16.46 | 4.29 | 2.65 | 2.35 | 2.27 | 7.40 | 11.87 | 1.80 |
| Cash Ratio | 11.38 | 11.38 | 13.94 | 15.91 | 3.66 | 2.27 | 1.93 | 1.62 | 7.18 | 11.66 | 1.80 |
| Asset Turnover | — | 0.11 | 0.13 | 0.06 | 0.03 | 0.38 | 0.30 | 0.28 | 0.04 | 0.06 | — |
| Inventory Turnover | — | — | 2.92 | 5.85 | — | 25.63 | 35.50 | 31.66 | 14.85 | — | — |
| Days Sales Outstanding | — | 100.51 | 46.23 | 139.38 | 197.61 | 49.08 | 55.99 | 73.12 | 82.29 | 52.75 | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 15.3% | 15.9% | — | 19.5% | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | 49.4% | — | 7.4% | — | — | — | — |
| Buyback Yield | 10.7% | 9.0% | 3.9% | 0.0% | 0.1% | 0.0% | 0.0% | 4.7% | 0.0% | 0.0% | 0.2% |
| Total Shareholder Yield | 10.7% | 9.0% | 3.9% | 0.0% | 0.1% | 0.0% | 0.0% | 4.7% | 0.0% | 0.0% | 0.2% |
| Shares Outstanding | — | $39M | $30M | $41M | $27M | $26M | $25M | $25M | $24M | $23M | $9M |
Structural Operating Margin Deficit
According to recent market data, GEG trades at a P/S multiple of 4.48, which appears disconnected from the company's negative operating margins and contracting revenue base, suggesting that investors may be mispricing the firm's transition toward a fee-based investment management model relative to its legacy medical operations.
The current P/E of 7.06 is likely distorted by non-recurring gains, rendering it an unreliable indicator of future earning power. Investors should monitor whether the market's valuation reflects a sum-of-the-parts reality or merely an optimistic expectation regarding the scalability of the investment management segment.
As reported in financial statements, GEG's profitability remains deeply strained, with gross margins plummeting to -55.3% in 2026Q3, a figure that highlights the fundamental inability of the legacy medical distribution segment to cover its direct costs in the current operating environment.
The extreme volatility in net margins, which swung from -140.1% to 33.5% over recent periods, suggests that core operational performance is frequently masked by non-recurring items. This lack of consistent profitability warrants extreme caution, as the company has yet to demonstrate a path to sustainable operating leverage.
Based on historical data, GEG's ROIC has remained consistently negative, reaching -6.2% in 2026Q3, which indicates that the company is currently destroying shareholder value rather than compounding it through its ongoing strategic pivot toward investment management services.
The persistent negative returns on capital suggest that the firm's asset base is not generating sufficient income to justify the capital employed. Investors should investigate whether the management team can improve capital efficiency or if the current structure is inherently incapable of producing positive returns.
According to quarterly filings, GEG's asset turnover ratio remains extremely low at 0.03, reflecting a significant underutilization of assets that complicates the company's ability to generate meaningful revenue from its existing medical equipment and investment management infrastructure.
The erratic nature of the cash conversion cycle, which has fluctuated wildly in recent quarters, suggests that the company lacks a stable operational rhythm. This inefficiency in managing working capital likely exacerbates the firm's liquidity pressures and limits its ability to pivot effectively.
As evidenced by the company's financial history, the P/E ratio is the most commonly misapplied metric for GEG, as it fails to account for the massive distortions caused by non-recurring divestiture gains and the structural shift from medical distribution to investment management.
Analysts should instead focus on a sum-of-the-parts valuation that separates the fee-based management income from the volatile DME segment. Relying on standard earnings multiples obscures the underlying cash burn and the high-risk dependency on a single BDC management contract.
Includes 30+ ratios · 28 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying GEG stock.
Great Elm Group, Inc.'s current P/E ratio is 6.5x. The historical average is 80.6x. This places it at the 50th percentile of its historical range.
Great Elm Group, Inc.'s return on equity (ROE) is 17.1%. The historical average is -27.0%.
Based on historical data, Great Elm Group, Inc. is trading at a P/E of 6.5x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Great Elm Group, Inc. has -0.7% gross margin and -49.0% operating margin.